Abstract
Editorial Commentary: Single-Dose Primaquine as Gametocytocidal Treatment in Patients With Uncomplicated Falciparum Malaria
Highlights
In this context, the well-designed and carefully executed open randomized controlled trial by Sutanto and colleagues published in this issue of Clinical Infectious Diseases makes a contribution to establish the risk-benefit profile of primaquine as an adjunct to artemisinin-based combination therapy (ACT) in the treatment of uncomplicated falciparum malaria in South Sumatra, Western Indonesia [3]
As a result of this consultation, the World Health Organization (WHO) recommends in areas threatened by artemisinin resistance, as well as in elimination areas, a single 0.25 mg base/kg primaquine dose for all patients with parasitologically confirmed falciparum malaria on the first day of treatment in addition to ACT without prior testing for G6PD deficiency
An optimal effect is predicted with a single primaquine dose on day 8, related to the fact that in falciparum malaria the peak in gametocyte density is usually delayed by around 1–2 weeks after the initial acute attack [10]
Summary
The well-designed and carefully executed open randomized controlled trial by Sutanto and colleagues published in this issue of Clinical Infectious Diseases makes a contribution to establish the risk-benefit profile of primaquine as an adjunct to ACT in the treatment of uncomplicated falciparum malaria in South Sumatra, Western Indonesia [3]. Patients were screened prior to randomization with a qualitative fluorescent spot test to detect G6PD deficiency.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
